vs

Side-by-side financial comparison of ACACIA RESEARCH CORP (ACTG) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.

Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $50.1M, roughly 1.4× ACACIA RESEARCH CORP). ACACIA RESEARCH CORP runs the higher net margin — 6.8% vs -49.0%, a 55.8% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 2.6%).

Acacia Research Corporation is a publicly traded American company based in New York City. It acquires and operates businesses in industries including the technology, energy, and industrial/manufacturing sectors. Acacia has a strategic relationship with Starboard Value, LP, the company's controlling shareholder. The company has been characterized as a patent troll.

Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.

ACTG vs VRDN — Head-to-Head

Bigger by revenue
VRDN
VRDN
1.4× larger
VRDN
$70.6M
$50.1M
ACTG
Growing faster (revenue YoY)
VRDN
VRDN
+81955.5% gap
VRDN
81958.1%
2.6%
ACTG
Higher net margin
ACTG
ACTG
55.8% more per $
ACTG
6.8%
-49.0%
VRDN

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ACTG
ACTG
VRDN
VRDN
Revenue
$50.1M
$70.6M
Net Profit
$3.4M
$-34.6M
Gross Margin
12.8%
Operating Margin
-26.1%
-56.7%
Net Margin
6.8%
-49.0%
Revenue YoY
2.6%
81958.1%
Net Profit YoY
125.5%
54.9%
EPS (diluted)
$0.03

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACTG
ACTG
VRDN
VRDN
Q4 25
$50.1M
Q3 25
$59.4M
$70.6M
Q2 25
$51.2M
Q1 25
$124.4M
Q4 24
$48.8M
Q3 24
$23.3M
Q2 24
$25.8M
Q1 24
$24.3M
Net Profit
ACTG
ACTG
VRDN
VRDN
Q4 25
$3.4M
Q3 25
$-2.7M
$-34.6M
Q2 25
$-3.3M
Q1 25
$24.3M
Q4 24
$-13.4M
Q3 24
$-14.0M
Q2 24
$-8.4M
Q1 24
$-186.0K
Gross Margin
ACTG
ACTG
VRDN
VRDN
Q4 25
12.8%
Q3 25
21.2%
Q2 25
12.8%
Q1 25
47.4%
Q4 24
17.6%
Q3 24
10.1%
Q2 24
26.2%
Q1 24
49.2%
Operating Margin
ACTG
ACTG
VRDN
VRDN
Q4 25
-26.1%
Q3 25
-10.8%
-56.7%
Q2 25
-24.2%
Q1 25
30.8%
Q4 24
-32.4%
Q3 24
-44.1%
Q2 24
-18.4%
Q1 24
-8.6%
Net Margin
ACTG
ACTG
VRDN
VRDN
Q4 25
6.8%
Q3 25
-4.6%
-49.0%
Q2 25
-6.4%
Q1 25
19.5%
Q4 24
-27.5%
Q3 24
-60.0%
Q2 24
-32.7%
Q1 24
-0.8%
EPS (diluted)
ACTG
ACTG
VRDN
VRDN
Q4 25
$0.03
Q3 25
$-0.03
Q2 25
$-0.03
Q1 25
$0.25
Q4 24
$-0.14
Q3 24
$-0.14
Q2 24
$-0.08
Q1 24
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACTG
ACTG
VRDN
VRDN
Cash + ST InvestmentsLiquidity on hand
$306.7M
$490.9M
Total DebtLower is stronger
$91.9M
Stockholders' EquityBook value
$543.5M
$503.0M
Total Assets
$771.0M
$577.1M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACTG
ACTG
VRDN
VRDN
Q4 25
$306.7M
Q3 25
$301.8M
$490.9M
Q2 25
$316.7M
Q1 25
$272.0M
Q4 24
$273.9M
Q3 24
$410.9M
Q2 24
$441.9M
Q1 24
$498.4M
Total Debt
ACTG
ACTG
VRDN
VRDN
Q4 25
$91.9M
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACTG
ACTG
VRDN
VRDN
Q4 25
$543.5M
Q3 25
$537.6M
$503.0M
Q2 25
$538.6M
Q1 25
$540.2M
Q4 24
$514.8M
Q3 24
$540.2M
Q2 24
$560.7M
Q1 24
$568.3M
Total Assets
ACTG
ACTG
VRDN
VRDN
Q4 25
$771.0M
Q3 25
$768.9M
$577.1M
Q2 25
$775.5M
Q1 25
$801.6M
Q4 24
$756.4M
Q3 24
$707.6M
Q2 24
$753.6M
Q1 24
$631.7M
Debt / Equity
ACTG
ACTG
VRDN
VRDN
Q4 25
0.17×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACTG
ACTG
VRDN
VRDN
Operating Cash FlowLast quarter
$75.2M
$-84.6M
Free Cash FlowOCF − Capex
$-84.7M
FCF MarginFCF / Revenue
-120.1%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
22.01×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACTG
ACTG
VRDN
VRDN
Q4 25
$75.2M
Q3 25
$9.5M
$-84.6M
Q2 25
$50.1M
Q1 25
$2.4M
Q4 24
$50.1M
Q3 24
$-593.0K
Q2 24
$16.1M
Q1 24
$54.8M
Free Cash Flow
ACTG
ACTG
VRDN
VRDN
Q4 25
Q3 25
$-84.7M
Q2 25
Q1 25
$335.0K
Q4 24
$-98.5M
Q3 24
$-2.8M
Q2 24
$-126.7M
Q1 24
$54.6M
FCF Margin
ACTG
ACTG
VRDN
VRDN
Q4 25
Q3 25
-120.1%
Q2 25
Q1 25
0.3%
Q4 24
-201.8%
Q3 24
-12.1%
Q2 24
-490.5%
Q1 24
224.4%
Capex Intensity
ACTG
ACTG
VRDN
VRDN
Q4 25
Q3 25
0.2%
Q2 25
Q1 25
1.7%
Q4 24
304.4%
Q3 24
9.6%
Q2 24
553.0%
Q1 24
1.1%
Cash Conversion
ACTG
ACTG
VRDN
VRDN
Q4 25
22.01×
Q3 25
Q2 25
Q1 25
0.10×
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACTG
ACTG

Energy Operations$16.0M32%
Transportation Safety$10.4M21%
Office Storage And Display Solutions$8.4M17%
Printers Consumables And Parts$6.5M13%
Natural Gas Reserves$5.1M10%
Natural Gas Liquids Reserves$3.3M7%

VRDN
VRDN

Segment breakdown not available.

Related Comparisons